Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Similar documents
NSPs in Estonia: current situation and future challenges

Harm Reduction in Nigeria

Technical Guidance Note for Global Fund HIV Proposals

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

COUNTRY TABLE. MONTENEGRO.

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

Access to needle and syringe exchange services in Estonia

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

HIV/AIDS INDICATORS. AIDS Indicator Survey 8 Basic Documentation Introduction to the AIS

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

STI and HIV Prevention and Care among Sex Workers

Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

Improving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative

Government of Canada Federal AIDS Initiative Milestones

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres

Hepatitis and HIV Co-Infection: Situation in Ukraine.

DEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS

Guidelines For Services Providing Injecting Equipment

Experiences of site visits to Estonian low threshold service centres - improving TB case-finding and infection control

HIV AND PEOPLE WHO INJECT DRUGS

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Prevention of and Immunisation against Hepatitis B and C

Models of good practice in drug treatment in Europe. Project group

Tajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan

Local Legislative Approval and Program Certification

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Protecting and Promoting Health and Equity

4th Asian Academic Society International Conference (AASIC) 2016 HEA-OR-095

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Figure 1: Newly diagnosed HIV-cases and total number of HIV-cases, (Data source: Estonian Health Board)

Report on the epidemiological situation of HIV and AIDS and the fulfilment of National HIV and AIDS Strategy for years in year 2012

EVALUATION TOOLS...123

HIV epidemic around the Baltic Sea

ATLAS on substance use 2017:

Sex Work in Sub-Saharan Africa : Opportunities and Challenges

APPLICANT REQUEST FOR MATCHING FUNDS. IMPORTANT: To complete this form, refer to the Instructions for Matching Funds Requests.

PERFORMANCE AND IMAGE ENHANCING DRUGS

Methods: respondent driven sampling (RDS) was used to recruit PWID

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

Who this handbook is for?

Diagnosis of HIV and TB in the Finnish primary health care. Pekka Suomalainen M.D

PERFORMANCE INDICATOR REFERENCE SHEETS FOR KEY POPULATIONS

FIGHTING HIV IN ESTONIA IN 2006 AND Aire Trummal, Liilia Lõhmus, Kristi Rüütel

Hepatitis prevention in the context of HIV prevention point work in Latvia

As a result of this training, participants will be able to:

As a result of this training, participants will be able to:

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

Strengthening the Evidence for HIV Investments: Allocative Efficiency of HIV Responses: Results and Experiences

Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018

OF THE REPUBLIC OF ARMENIA DECREE. 316 of 1 April 2002 Yerevan

Prevention of and Immunisation against Hepatitis B and C

Blood-borne viruses in marginalised populations

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

Needle Exchange Programs

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

QuADS Organisational Standards and Professional Competencies in needle exchange

COLLABORATIVE RESEARCH ON HIV AMONG PERSONS WHO INJECT DRUGS IN TALLINN, ESTONIA, PRESENT

Hepatitis C Strategy. About us. What is hepatitis C?

January Treatment Centre. December Drop-In Centre. November Regional Office

Needle and Syringe Programs - 17 October 2013

GLOBAL AIDS MONITORING REPORT

UNGASS COUNTRY PROGRESS REPORT Republic of Armenia

NATIONAL PROGRAMME ON THE RESPONSE TO THE HIV EPIDEMIC

MINISTRY OF HEALTH STRATEGIC FRAMEWORK OF COMMUNICATION FOR HIV/AIDS AND STIs INTRODUCTION

New trends in harm reduction in Europe: progress made challenges ahead

Towards universal access

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

GLOBAL AIDS RESPONSE PROGRESS REPORTING (GARPR) 2014 COUNTRY PROGRESS REPORT SINGAPORE

Promoting hepatitis B vaccination

4.0 Current Service Configuration

Adapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access -

KENYA AIDS STRATEGIC FRAMEWORK 2014/ /2019

Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project

Program to control HIV/AIDS

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

Becoming a harm reduction distribution agency in Toronto - information session

Jefferson County Syringe Exchange Program (SEP) Annual Report 2017

National HIV Behavioral Surveillance Portland, Oregon

Targeted Outreach & Other Strategies for Increasing HCV Testing

increased efficiency. 27, 20

Prevention of and Immunisation against Hepatitis B and C

Essential minimum package ALHIV service provision: Community level

Hepatitis C : Screening and Prevention Strategies

Substance use and misuse

epidemic among vulnerable groups

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

Estimating resource needs and gaps for harm reduction in Asia

PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE

Sexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012

State HIV Allocations in Baltimore

IMPORTANT HEALTH INFORMATION

Country progress report - Bangladesh. Global AIDS Monitoring 2017

Available In person Courses

Transcription:

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs Aljona Kurbatova National Institute for Health Development Estonia

Estimated number of people who inject drugs In 2005, it was estimated that there were almost 14,000 PWID in Estonia, with a prevalence of 2.4% among 15 44-year-olds. There appears to be a decline in the number of PWID. The population size is estimated to be around 9,000. 70% are injecting fentanyl and its analogues (3-methylfentanyl). PWID are mostly confined to two regions capital city Tallinn (including its surrounding county Harjumaa), and North-Easter Estonia (Ida-Viru county)

Core of the problem Drug use is untreatable selfinflicted behaviour There are other people who deserve help more Services not adjusted to the needs of people with lesser coping skills/possibilities. Main challenges: How to win the trust of the vulnerable groups (how to overcome the stigma, fear of disclosure and discrimination). How to create an enabling environment. How to deal not only with the problem itself but also its underlying determinants. www.tai.ee/en/tubidu

National public health strategies UNTIL 2012 National HIV/AIDS prevention strategy 2006 2015 National drug abuse prevention strategy until 2012 National tuberculosis prevention and treatment strategy 2008 2012 National cardio-vascular disease prevention strategy 2005 2020 National cancer prevention strategy 2007 2015 Program for safe and healthy development of children and young peole (as part of the Estonian National Health Plan 2009-2020) No separate strategy for prevention and control of Hepatatis B and C or other STIs and BBVs. FROM 2013 all public health strategies and initiatives are integrated into one comprehensive program - National Health Plan 2009-2020

National response to the problem Harm reduction programs for people who inject drugs Needle and syringe exchange programs Psychosocial services Overdose prevention (including take-home naloxone) HIV testing and counselling (based on risk behaviors and indicator conditions) and STI testing Voluntary HIV testing and counselling (including rapid testing in non-medical settings) Piloting of the Internet-facilitated STI testing for MSM STI testing, treatment and counselling services for CSW STI testing, treatment and counselling services for uninsured young people Includes Hepatitis B and C testing HIV-related health care services including HAART (free of charge for all) TB-related health care services including treatment (free of charge for all) Drug treatment and rehabilitation Opioid substitution treatment Inpatient detoxification Inpatient rehabilitation Outpatient psychosocial counseling Outpatient treatment for people with dual diagnosis

Funding of the national response All activities are fully funded from the state budget: National Health Plan (through National Institute for Health Development under Ministry of Social Affairs) Harm reduction services Drug treatment, rehabilitation and counselling Voluntary HIV, Hepatitis B and C testing STI testing for vulnerable groups Emergency Health Care services (through Ministry of Social Affairs) Treatment of accute conditions for people without health insurance Health Insurance Fund Treatment for people with health insurance

Addressing Hepatitis B and C within harm reduction services Condoms, extra strongs condoms and lubricants are provided to all clients without quantity limitations. Wide selection of needles and syringes, dry and alcohol pads is provided to all clients without quantity limitations. However, low dead-space syringes are not provided yet. Injecting equipment and condoms are disseminated on site, during outreach and through secondaries. Sexual health and safer injecting advice must be provided by staff of HR sites (including peers).

Addressing Hepatitis B and C within harm reduction services Staff of the HR services (including peers) is regularly trained on STIs and BBVs including Hepatitis B and C. Staff of the HR services (including peers) is trained on safer injecting practices. Free of charge and anonymous testing is available to PWID at voluntary counselling and testing sites. Informational materials are available for PWID and staff of the HR services must inform them about hepatitis risks, possibilities for diagnosis and treatment (including during outreach work). Informing about hepatitis is mostly done by peers.

Achieved level of services: Needle and syringe programme in Estonia In 2014 37 needle/syringe exchange sites:13 fixed, 24 outreach sites. Located in capital area (Tallinn, Maardu), Central-Estonia (Tapa, Paide) and North-East Estonia. Estimated coverage of the PWID is ~60% (6 677 clients/estimated population size ~9 000).

Mean age has increased from 23 to 32 years Mean age was 32 years in 2013 (range 18 to 59 years) Females were slightly younger than males (30 years versus 33 years, p=0.006) 70 60 Age in years 50 40 30 20 Range Mean age 10 0 2003 2004 2005 2007 2009 2013

NSP is an essential source for clean syringes Sharing of used syringes (last 4 weeks): Main sources for clean syringes (last 4 weeks) in 2013: % 60 50 54 Syringe exchange program n % 210 64,0 40 30 20 35 29 23 Pharmacy 76 23,2 Friends 20 6,1 Outreach worker 5 1,5 Other people who inject drugs 4 1,2 10 Family 3 0,9 0 2005 2007 2009 2013 Drug dealer 1 0,3

The nine interventions in the comprehensive HIV prevention package 1. Needle and syringe programmes 2. Opioid substitution therapy and other drug dependence treatment 3. HIV testing and counselling 4. Antiretroviral therapy 5. Prevention and treatment of sexually transmitted infections 6. Condom programmes for people who inject drugs and their sexual partners 7. Targeted information, education and communication for people who inject drugs and their sexual partners 8. Vaccination, diagnosis and treatment of viral hepatitis 9. Prevention, diagnosis and treatment of tuberculosis.

Guidance on prevention of viral hepatitis B and C among people who inject drugs Recommendation 1: It is suggested to offer people who inject drugs the rapid hepatitis B vaccination regimen. Recommendation 2: It is suggested to offer people who inject drugs incentives to increase uptake and completion of the hepatitis B vaccine schedule. Recommendation 3: It is suggested that needle and syringe programs also provide low dead-space syringes for distribution to people who inject drugs. Recommendation 4: Psychosocial interventions are not suggested for people who inject drugs to reduce the incidence of viral hepatitis. Recommendation 5: It is suggested to offer peer interventions to people who inject drugs to reduce the incidence of viral hepatitis.

What needs to be improved All recommendations need to be implemented. It is, after all, much cheaper than not implementing them.

Thank you!